BLAM
PACB icon

Bourne Lent Asset Management’s Pacific Biosciences PACB Stock Holding History

Bourne Lent Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Sell
951,055
-16,000
-2% -$28.6K 0.46% 29
2025
Q4 		$1.81M Hold
967,055
– – 0.6% 29
2025
Q3 		$1.24M Sell
967,055
-5,200
-0.5% -$7.04K 0.44% 30
2025
Q2 		$1.21M Hold
972,255
– – 0.47% 30
2025
Q1 		$1.15M Buy
972,255
+28,500
+3% +$43.7K 0.49% 29
2024
Q4 		$1.73M Sell
943,755
-10,840
-1% -$21.2K 0.66% 26
2024
Q3 		$1.62M Buy
954,595
+3,200
+0.3% +$5.26K 0.62% 27
2024
Q2 		$1.3M Buy
951,395
+296,980
+45% +$600K 0.5% 29
2024
Q1 		$2.45M Buy
654,415
+62,200
+11% +$364K 0.99% 19
2023
Q4 		$5.81M Buy
592,215
+17,865
+3% +$146K 2.36% 12
2023
Q3 		$4.8M Sell
574,350
-5,650
-1% -$64.6K 2.11% 13
2023
Q2 		$7.71M Sell
580,000
-11,450
-2% -$139K 2.69% 11
2023
Q1 		$6.85M Hold
591,450
– – 2.59% 11
2022
Q4 		$4.84M Buy
591,450
+7,300
+1% +$62.9K 2.07% 13
2022
Q3 		$3.39M Buy
584,150
+25,285
+5% +$145K 1.47% 16
2022
Q2 		$2.47M Buy
558,865
+2,000
+0.4% +$12.2K 0.98% 20
2022
Q1 		$5.07M Buy
556,865
+1,115
+0.2% +$12.8K 1.59% 15
2021
Q4 		$11.4M Buy
555,750
+2,900
+0.5% +$70K 3.04% 11
2021
Q3 		$14.1M Buy
552,850
+4,000
+0.7% +$119K 4.05% 9
2021
Q2 		$19.2M Buy
548,850
+12,050
+2% +$350K 5.39% 7
2021
Q1 		$17.9M Buy
536,800
+1,850
+0.3% +$64.8K 5.71% 6
2020
Q4 		$13.9M Sell
534,950
-21,000
-4% -$357K 4.57% 7
2020
Q3 		$5.49M Sell
555,950
-450
-0.1% -$2.59K 2.11% 12
2020
Q2 		$1.92M Hold
556,400
– – 0.83% 18
2020
Q1 		$1.7M Buy
556,400
+114,750
+26% +$470K 0.91% 19
2019
Q4 		$2.27M Hold
441,650
– – 1.07% 18
2019
Q3 		$2.28M Buy
441,650
+106,000
+32% +$593K 1.09% 16
2019
Q2 		$2.03M Hold
335,650
– – 0.97% 18
2019
Q1 		$2.43M Hold
335,650
– – 1.2% 15
2018
Q4 		$2.48M Buy
335,650
+8,500
+3% +$53.9K 1.47% 15
2018
Q3 		$1.77M Hold
327,150
– – 0.84% 19
2018
Q2 		$1.16M Buy
327,150
+9,498
+3% +$26.3K 0.61% 24
2018
Q1 		$651K Buy
317,652
+26,200
+9% +$68K 0.35% 31
2017
Q4 		$769K Buy
291,452
+89,002
+44% +$312K 0.41% 31
2017
Q3 		$1.06M Buy
202,450
+4,000
+2% +$17.2K 0.55% 25
2017
Q2 		$706K Sell
198,450
-4,500
-2% -$18.1K 0.39% 30
2017
Q1 		$1.05M Hold
202,950
– – 0.57% 25
2016
Q4 		$771K Buy
202,950
+22,400
+12% +$163K 0.46% 28
2016
Q3 		$1.62M Buy
180,550
+4,200
+2% +$35.1K 1.19% 15
2016
Q2 		$1.24M Buy
176,350
+13,000
+8% +$119K 0.98% 19
2016
Q1 		$1.39M Buy
163,350
+18,575
+13% +$183K 1.11% 18
2015
Q4 		$1.9M Sell
144,775
-10,000
-6% -$89.7K 1.44% 12
2015
Q3 		$566K Buy
154,775
+2,200
+1% +$10.8K 0.46% 29
2015
Q2 		$879K Buy
152,575
+5,000
+3% +$28.9K 0.69% 24
2015
Q1 		$862K Buy
+147,575
New +$1.02M 0.65% 24

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bourne Lent Asset Management's PACB Position: Q1 2026 in Review

Bourne Lent Asset Management reduced its Pacific Biosciences (PACB) stake by 1.7% in Q1 2026, selling an estimated $28.6K and leaving 951,055 shares worth $1.26M. The position accounts for 0.46% of the portfolio, ranked #29.

Bourne Lent Asset Management first reported a position in PACB in Q1 2015 and has held it in 45 quarters since. The position peaked at $19.2M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Bourne Lent Asset Management held 951,055 shares of Pacific Biosciences worth $1.26M as of Q1 2026.
  • Bourne Lent Asset Management sold 16,000 Pacific Biosciences shares in Q1 2026, an estimated $28.6K.
  • Pacific Biosciences made up 0.46% of Bourne Lent Asset Management's portfolio in Q1 2026, its #29 holding.
  • Bourne Lent Asset Management first reported a position in Pacific Biosciences in Q1 2015 and has held it in 45 quarters since.
  • Bourne Lent Asset Management's Pacific Biosciences position peaked at $19.2M in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Bourne Lent Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.